Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Goodwin Launches New Women's Health Group (Law360)

Related Content

Health Headlines: November 2025

Health Headlines: October 2025

Health Headlines: September 2025

Health Headlines: August 2025

Health Headlines: July 2025

Changes to Birthright Citizenship and the Impact on Fertility and Assisted Reproduction Clinics

Health Headlines: June 2025

Texas District Court Vacates HIPAA Reproductive Healthcare Rule

Katherine Baudistel Recognized by Los Angeles Business Journal’s 2025 Leaders of Influence in Private Equity

FemHealth Ventures Closes $32 Million Fund for Women’s Health Investments (The Wall Street Journal)

Texas Abortion Drug Ruling Could Create ‘Slippery Slope’ for FDA Approvals, Drug Research and Patients, Experts Say (CNN)

6 Burning Questions About How the FDA Will Handle Conflicting Abortion Pill Decisions (STAT)

Federal Judge Rules to Freeze Use of Abortion Pill Nationwide (Axios)

Analysis: Texas Abortion Pill Ruling Could Disrupt U.S. Drug Oversight (Reuters)

Abortion Pill Ruling Looms Over FDA's Drug Approval Process (Axios)

Abortion Pill Court Docket Delay Concerns Legal Advocates (Bloomberg Law)

Women’s Health and Wellness

Private Equity

Healthcare

Technology

Life Sciences

Real Estate

Financial Services

Medtech

Complex Litigation & Dispute Resolution

Litigation